文献速递肺栓塞与肺血管病

左心疾病危险因素对肺动脉高压治疗结局的影响

Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
PubMed 文献 · Chest · 2023-11-10

基于澳大利亚与新西兰肺高压登记注册的队列研究,采用AMBITION试验标准界定合并左心疾病(LHD)危险因素的肺动脉高压(PAH)患者,比较其治疗策略、功能结局与生存。共纳入487例新诊断PAH患者,其中103例(21.1%)符合PAH伴LHD危险因素定义;该组较少接受初始联合治疗(27% vs 44%),但12个月6分钟步行距离变化与参考组相似,REVEAL 2.0风险评分在两组均有良好区分度,两组生存无差异。

要点

  • PAH伴LHD危险因素者初始联合治疗比例低于参考组(27% vs 44%)。
  • 该组12个月6分钟步行距离改善与参考组相似,功能分级改善亦相似。
  • 两组生存无差异,REVEAL 2.0风险评分在两组均有良好风险区分度。

核心结论

  • 在真实世界队列中,伴LHD危险因素的PAH患者较少接受初始联合治疗,但接受初始联合治疗的特定患者功能应答与参考组相似。
  • 需进一步研究对心肺合并症PAH患者进行表型分型,以识别可能从初始联合治疗中获益者。

研究设计与样本

  • 研究使用AMBITION试验标准界定伴LHD危险因素的PAH表型,并与澳大利亚与新西兰肺高压学会登记注册的参考PAH队列比较。
  • 纳入2011至2020年新诊断PAH患者共487例,其中103例(21.1%)符合PAH伴LHD危险因素定义,384例(78.9%)为参考组。

主要发现

  • PAH伴LHD危险因素组年龄更大(66 ± 13 vs 58 ± 19岁;P < .001),肺血管阻力更低(393 ± 266 vs 708 ± 391 dyn.s/cm5;P = .031),诊断时6分钟步行距离更差(286 ± 130 vs 327 ± 136 m;P = .005)。
  • 该组较少接受初始联合治疗(27% vs 44%;P = .02)。
  • 12个月6分钟步行距离变化两组相似(43 ± 77 m vs 50 ± 90 m;P = .50);按初始治疗分层,单药治疗为40 ± 81 vs 38 ± 95 m(P = .87),联合治疗为53 ± 78 vs 64 ± 106 m(P = .511)。
  • REVEAL Registry 2.0风险评分在两组区分度良好(C statistic = 0.756 vs 0.750),两组生存无差异(log-rank检验 P = .29)。

临床怎么用

  • 对伴LHD危险因素的PAH患者,初始联合治疗应用较少,但特定患者接受联合治疗可获得与参考组相似的功能应答。
  • REVEAL 2.0风险评分可用于该人群的风险分层,生存随访结果与参考组无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend initial monotherapy for pulmonary arterial hypertension (PAH) with cardiopulmonary comorbidities, despite limited available evidence to guide management. RESEARCH QUESTION: Do left heart disease (LHD) risk factors have an impact on treatment response and influence applicability of risk assessment in a real-world cohort of patients with PAH? STUDY DESIGN AND METHODS: The Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial criteria was used to define the phenotype of patients with PAH with risk factors for LHD. Treatment strategy, functional outcome, long-term survival, and risk discrimination were compared with a reference PAH cohort using the Pulmonary Hypertension Society of Australia and New Zealand Registry. RESULTS: A total of 487 incident patients with PAH diagnosed between 2011 and 2020 were included. Of these, 103 (21.1%) fulfilled the definition of PAH with LHD risk factors, with 384 (78.9%) remaining as the reference group. Patients in the PAH with LHD risk factors group were older (66 ± 13 vs 58 ± 19 years; P < .001), had lower pulmonary vascular resistance (393 ± 266 vs 708 ± 391 dyn.s/cm5; P = .031), and had worse 6-min walk distance (286 ± 130 vs 327 ± 136 m; P = .005) at diagnosis. The PAH with LHD risk factors group was less likely to receive initial combination therapy (27% vs 44%; P = .02). Changes in 6-min walk distance at 12 months were similar in both groups (43 ± 77 m in the PAH with LHD risk factors group and 50 ± 90 m in the reference group; P = .50), including when stratified by initial treatment strategy (PAH with LHD risk factors group vs reference PAH group: monotherapy: 40 ± 81 vs 38 ± 95 m, P = .87; combination therapy: 53 ± 78 vs 64 ± 106 m, P = .511). Functional class improvements were also similar in both groups. REVEAL Registry 2.0 risk score effectively discriminated risk in both populations (C statistic = 0.756 for the PAH with LHD risk factors group and C statistic = 0.750 for the reference PAH group). There was no difference in survival between the two groups (log-rank test, P = .29). INTERPRETATION: In a real-world cohort, patients with PAH with LHD risk factors were less likely to be exposed to initial combination therapy. Nevertheless, selected patients with PAH with LHD risk factors who were treated with initial combination therapy derived similar functional response compared with the reference group. Further studies are needed to phenotype patients with PAH with cardiopulmonary comorbidities who may benefit from initial combination therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kearney K, Brown K, Celermajer DS, et al. Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy. Chest. 2023. PMID: 37951349. doi:10.1016/j.chest.2023.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。